Skip to main content

The neuropsychiatry of multiple sclerosis

  • Maria A. Ron

Multiple sclerosis (MS), an immune-mediated demyelinating condition, is the most common neurological disease affecting young adults in the UK. It has a high psychiatric comorbidity and over half of patients have some degree of cognitive impairment that adds to the burden of disability. This article reviews the psychiatric and cognitive manifestations of MS and their detection and treatment. Recent advances in the treatment of the disease are briefly reviewed and the impact of disease-modifying therapies on psychiatric morbidity and cognitive impairment is discussed.


  • Understand the psychiatric morbidity in MS and its biological counterparts
  • Understand the cognitive impairment and its biological counterparts
  • Become familiar with the detection and treatment of the psychiatric and cognitive manifestations of MS



Corresponding author
Correspondence Professor Maria A. Ron, 24 Claylands Road, London SW8 1NZ, UK. Email:
Hide All
Andreassen, OA, Harbo, HF, Wang, Y, et al. (2015) Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Molecular Psychiatry, 20: 207–14.
Bamer, AM, Cetin, K, Johnson, KL, et al. (2008) Validation study of prevalence and correlates of depressive symptomatology in multiple sclerosis. General Hospital Psychiatry, 30: 311–7.
Benedict, RH, Munschauer, F, Zarevics, P, et al. (2008) Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients. Journal of Neurology, 255: 848–52.
Benros, ME, Eaton, WW, Mortensen, PB (2014) The epidemiologic evidence linking autoimmune diseases and psychosis. Biological Psychiatry, 75: 300–6.
Chiaravalloti, ND, Genova, HM, DeLuca, J (2015) Cognitive rehabilitation in multiple sclerosis: the role of plasticity. Frontiers in Neurology, 6: 67.
Cotter, J, Firth, J, Enzinger, C (2016) Social cognition in multiple sclerosis: a systematic review and meta-analysis. Neurology, 87: 1727–36.
Cottrell, S, Wilson, S (1926) The affective symptomatology of disseminated sclerosis: a study of 100 cases. Journal of Neurological Psychopathology, 7: 130.
Ensari, I, Motl, RW, McAuley, E, et al. (2014) Patterns and predictors of naturally occurring change in depressive symptoms over a 30-month period in multiple sclerosis. Multiple Sclerosis, 20: 602–9.
Feinstein, A (2002) An examination of suicidal intent in patients with multiple sclerosis. Neurology, 59: 674–8.
Feinstein, A, Banwell, E, Pavisian, B (2015) What to make of cannabis and cognition in MS: in search of clarity amidst the haze. Multiple Sclerosis Journal, 21: 1755–60.
Feinstein, A, du Boulay, G, Ron, MA (1992) Psychotic illness in multiple sclerosis: a clinical and magnetic resonance imaging study. British Journal of Psychiatry, 161: 680–5.
Feinstein, A, Magalhaes, S, Richard, JF, et al. (2014) The link between multiple sclerosis and depression. Nature Reviews, Neurology, 10: 507–17.
Feinstein, A, O'Connor, P, Akbar, N, et al. (2010) Diffusion tensor imaging abnormalities in depressed multiple sclerosis patients. Multiple Sclerosis, 16: 189–96.
Fernie, BA, Kollmann, J, Brown, RG (2015) Cognitive behavioural interventions for depression in chronic neurological conditions: a systematic review. Journal of Psychosomatic Research, 78: 411–9.
Fiest, KM, Walker, JR, Bernstein, CN, et al. (2016) Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 5: 1226.
Foong, J, Rozewicz, L, Quaghebeur, G, et al. (1997) Executive function in multiple sclerosis. The role of frontal lobe pathology. Brain, 120: 1526.
Gobbi, C, Rocca, MA, Riccitelli, G, et al. (2014) Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Multiple Sclerosis, 20: 192201.
Gold, S, Kern, K, O'Connor, M (2010) Smaller cornu ammonis, 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biological Psychiatry, 68: 553–9.
Harel, Y, Appleboim, N, Lavie, M, et al. (2009) Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process. Journal of Neurological Sciences, 276: 3840.
Hulst, HE, Goldschmidt, T, Nitsche, MA, et al. (2017) rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 88: 386–94.
Lacy, M, Hauser, M, Pliskin, N, et al. (2013) The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study. Multiple Sclerosis, 19: 1765–72.
Marrie, RA, Cohen, J, Stuve, O, et al. (2015) A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Multiple Sclerosis, 21: 263–81.
Minden, SL, Feinstein, A, Kalb, RC, et al. (2014) Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 82: 174–81.
Mohr, DC, Hart, SL, Fonareva, I, et al. (2006) Treatment of depression in patients with multiple sclerosis in neurological clinics. Multiple Sclerosis, 12: 204–8.
Morrow, SA, Smerbeck, A, Patrick, K, et al. (2013) Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study. Journal of Neurology, 260: 489–97.
Muhlert, N, Sethi, V, Schneider, T, et al. (2013) Diffusion MRI-based cortical complexity alterations associated with executive function in multiple sclerosis. Journal of Magnetic Resonance Imaging, 38: 5463.
Muhlert, N, Sethi, V, Cipolotti, L, et al. (2015) The grey matter correlates of impaired decision making in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 86: 530–6.
Nigro, S, Passamonti, L, Riccelli, R, et al. (2015) Structural ‘connectomic’ alterations in the limbic system of multiple sclerosis patients with major depression. Multiple Sclerosis, 21: 1003–12.
Nygaard, G, Walhovd, K, Sowa, P (2015) Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Multiple Sclerosis, 21: 402–14.
O'Brien, A, Chiaravalloti, N, Goverover, Y, et al. (2008) Evidence-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Archives of Physical Medicine and Rehabilitation, 89: 761–9.
Passamonti, L, Cerasa, A, Liguori, M, et al. (2009) Neurobiological mechanisms underlying emotional processing in relapsing-remitting multiple sclerosis. Brain, 132: 3380–91.
Patten, S, Svenson, L, Metz, L (2005) Psychotic disorders in MS: population-based evidence of an association. Neurology, 65: 1123–5.
Patti, F, Amato, M, Bastianello, S, et al. (2009) Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing remitting multiple sclerosis: 2-years results from the COGIMUS study. Therapeutic Advances in Neurological Disorder, 2: 6777.
Pioro, EP (2014) Review of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA®) for pseudobulbar affect, Neurology and Therapy, 3: 15–28.
Price, A, Rayner, L, Okon-Rocha, E, et al. (2011) Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomized control trials. Journal of Neurology, Neurosurgery and Psychiatry, 82: 914–23.
Rocca, MA, Pravatà, E, Valsasina, P, et al. (2015) Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. Human Brain Mapping, 36: 5051–63.
Scalfari, A, Knappertz, V, Cutter, G, et al. (2013) Mortality in patients with multiple sclerosis. Neurology, 81: 184–92.
Solomon, A, Weinshenker, B (2013) Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. Current Neurology and Neuroscience Reports, 13: 403.
Strober, LB, Arnett, PA (2010) Assessment of depression in multiple sclerosis: development of a “trunk and branch” model. Clinical Neuropsycholy, 24: 1146–66.
Sumowski, JF, Wylie, GR, Deluca, J, et al. (2010) Intellectual enrichment is linked to cerebral efficiency in multiple sclerosis: functional magnetic resonance imaging evidence for cognitive reserve. Brain, 133: 362–74.
Titulaer, MJ, Höftberger, R, Iizuka, T, et al. (2014) Overlapping demyelinating syndromes and anti–N-methyl-d-aspartate receptor encephalitis. Annals of Neurology, 75: 411–28.
Weinstock-Guttman, B, Galetta, SL, Giovannoni, G, et al. (2012) Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. Journal of Neurology, 259: 898905.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Advances
  • ISSN: 2056-4678
  • EISSN: 2056-4686
  • URL: /core/journals/bjpsych-advances
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed

The neuropsychiatry of multiple sclerosis

  • Maria A. Ron
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *